Estimated Time to Complete Educational Activity
In this web-based program, physicians will learn how recent developments in genomic and clinical research have helped to advance the management of cancer.
February 7, 2017
February 7, 2019
Method of Physician Participation Utilized in Learning Process
There are no fees for participating and receiving CME credit for this activity. During the period February 7, 2017 through February 7, 2019 participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity, and are expected to view all 7 segments totaling 2.5 hours to successfully complete the activity and earn CME credit; 3) register and complete the evaluation form and post-test; 4) score 100% on the post-test; and 5) print out your CME certificate.
Participation in this WebCAST is complimentary, and clinicians are invited to view this CME-certified program and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals..
Supported by an educational grant from Roche Singapore Pte Ltd
This activity has been planned and implemented in accordance with accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Massachusetts Medical School and CMEducation Resources, LLC. University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The University of Massachusetts Medical School designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Policy on Faculty & Provider Disclosure
It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.
American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credits™ from organizations accredited by the ACCM.
Program Faculty and Disclosure
Professor Nir Peled, MD, PhD, FCCP – Program Chair
Head of the Thoracic Cancer Unit and the Center for Precision Cancer Care
Davidoff Cancer Center
Tel Aviv University
Tel Aviv, Israel
Advisor for and honorarium from AstraZeneca, Boehringer Ingelheim, BMS, Lilly , MSD, Novartis, Pfizer, Roche
Professor Rebecca Dent, MD, FRCP
Clinical Sciences Consultant, Medical Oncology
National Cancer Centre, Singapore
Associate Scientist, Sunnybrook Research Institute
Assistant Professor, Department of Medical Oncology
University of Toronto
Toronto, Ontario Canada
Travel grants, honoraria and/or speaker fees from: AstraZeneca, Celgene, Eisai, Genentech, Merck, Novartis, Pfizer, Roche
Professor Maria Li Lung, PhD
Chair and Professor of the Department of Clinical Oncology
The University of Hong Kong
Director of Laboratory of Cancer Molecular Genomics
Director, Area of Excellence Center for Nasopharyngeal Carcinoma Research
The University of Hong Kong
Non-paid consultant for OncoSeek working on CTCs
Dr. Brendan Pang, MBBS, FRCPath (UK)
Consultant, Department of Pathology Laboratory (Section)
Director, Diagnostic Molecular Oncology Centre (DMOC)
National University Hospital (NUH)
Clinical Assistant Professor
Clinician Tract, Department of Pathology
Yong Loo Lin School of Medicine
National University Singapore (NUS)
Honorariums and/or speaker fees for consulting, speaking, and advisory boards from:
MSD, Roche, AstraZeneca
Dr David SP Tan, BSc(Hons), MBBS(Hons)(London), MRCP(UK) (Medical Oncology), PhD(London), FRCP(Edin)
Consultant Medical Oncologist
National University Cancer Institute
Assistant Professor, Department of Medicine
Yong Loo Lin School of Medicine
National University Cancer Institute, Singapore (NCIS)
Head, Innovation Transfer Office (Research Office)
National University Health System (NUHS)
Consultant/Advisory Role: Astra Zeneca, Roche, D3 Singapore
Honoraria: Astra Zeneca, Roche
Research Funding: Astra Zeneca, Karyopharm Therapeutics, National Medical Research Council (NMRC) Singapore, National University Hospital Cancer Institute Singapore (NCIS) Endowment fund, NCIS Centre Grant Expert Testimony: None Other Remuneration: Merck
Dr. Wong Seng Weng, MBBS, MRCP(UK), FAMS (Medical Oncology)
Medical Director & Consultant Medical Oncologist
The Cancer Centre (Singapore Medical Group)
Paragon Medical & Mt Elizabeth Novena Specialist Centre
Mt Elizabeth Hospital & Mt Elizabeth Novena Hospital
Adjunct Clinician Scientist
Institute of Bioengineering & Nanotechnology (IBN) Agency for Science, Technology & Research (A*STAR)
Honoraria: Astra Zeneca, Bayer, Schering Pharma, Bristol-Myers Squibb, Eisai, Eli Lilly, Hospira, Merck Serono, Merck Sharp & Dohme (MSD), Mundipharma, Novartis, Orient Europharma., Pfizer, Roche
Advisory Boards: Astra Zeneca, Bayer Schering Pharma, Bristol-Myers Squibb, Eli Lilly, Hospira, Merck Serono, Merck Sharp & Dohme (MSD), Novartis, Orient Europharma, Pfizer, Roche
Professor James CH Yang, MD, PhD
Professor, Graduate Institute of Oncology
National Taiwan University
Director, Department of Oncology
National Taiwan University Hospital
Honoraria for speeches or advisory board duties from Boehringer Ingelheim, Eli Lilly, Bayer, Roche/Genentech/Chugai, Astellas, MSD, Merck Serono, Pfizer, Novartis, Clovis Oncology, Celgene, Merrimack, Yuhan Pharmaceuticals, BMS, Ono Pharmaceutical, Daiichi Sankyo and AstraZeneca
Upon completion of this activity, participants will be able to:
- Compare and contrast the various technologies used to detect actionable mutational targets in cancer
- Identify actionable mutational targets and targeted therapies across the spectrum of cancer
- Explain the differences—sensitivity, specificity, and utility—between hot spot panels and hybrid capture NGS comprehensive genomic profiling
- Detail how evidence-based deployment of genomic profiling can improve clinical outcomes in cancer
- Identify which patient populations are appropriate candidates for NGS-based assessments and interpret and act upon results of NGS mutational testing.
Hardware and Software Requirements:
To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to print out the CME certificate.
When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:
- We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
- For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
- We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
- If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.
Copyright © 2017 by CMEducation Resources, LLC All rights reserved.
Reproduction, distribution, or translation without express written permission is strictly prohibited.
Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.
Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.
Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.
Opinions expressed herein are not necessarily those of CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.